Immunosuppression, Rheumatism Don’t Up Breakthrough COVID Risk

Patients with immunomodulated inflammatory diseases are not at higher risk for breakthrough COVID-19 infections, apart from those on anti-CD20 therapy, according to findings from several new studies.
Medscape Medical News